Agile Therapeutics Receivables

Agile Therapeutics (AGRX) currently reports a receivables of $4.6M as of June 2024. That compares with $4.5M in the prior-year period — up 2.0% year over year. Use the charts on this page to explore Agile Therapeutics's receivables history and peer comparisons.

Agile Therapeutics's receivables increased from $4.5M to $4.6M — a 2.0% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Agile Therapeutics reported $4.6M in receivables as of June 2024. That compares with $4.5M in the prior-year period — up 2.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $4.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Agile Therapeutics, and consider following AGRX for alerts when major investors trade the stock.

Agile Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $4.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGRX with unrelated industries.